openPR Logo
Press release

First patient in Malaysia successfully treated with Urolastic™ - collaboration between Leader Biomedical and Urogyn yields first results

09-26-2017 01:00 PM CET | Health & Medicine

Press release from: Leader Biomedical

Urogyn B.V. and Leader Biomedical announce the first patient treated in Malaysia with Urolastic™– an innovative Urinary Stress Incontinence product that is exclusively offered by Leader Biomedical in India and APAC.
We are excited to announce that we have successfully introduced Urolastic™ in Malaysia and treated a female patient suffering from severe Stress Urinary Incontinence (SUI). The patient suffered from the condition, as a result of birth deficiencies and was diagnosed with a short, yet very wide urethra. After previously undergoing a procedure using a bulking agent, the patient went down from using eight pads a day, to five pads a day. Treatment with Urolastic™ earlier this month by Dr. Warren Lo Hwa Loon at Pantai Hospital Kuala Lumpur has improved the patient’s condition, as a result of which she now only uses one pad a day, thus significantly improving her quality of life.

Stress Urinary Incontinence is a disease affecting over 200 million people worldwide. Traditionally, SUI is treated with either a sling or injection of a bulking agent, where a sling procedure is an invasive procedure for the patient and the traditional bulking agents are expensive, as they are only effective for a short period and need to be repeated regularly.

“Patients who would benefit from bulking agent procedure are those that suffered from a failed sling procedure, elderly patients that are happy with a positive effect and incontinence reduction rather than a guaranteed total stop of leakage, and patients that prefer minimally-invasive surgery as opposed to sling procedure surgery” shares Dr. Warren Lo Hwa Loon, Pantai Hospital Kuala Lumpur.
“Urolastic™ is the most effective bulking agent available to patients suffering from SUI. The agent stays at the application site since it is not a fluid in the body, but hardens to form a solid mass. Also, treatment with Urolastic™ is an outpatient procedure in most cases. In addition to being an attractive procedure for the elderly and after failed sling procedures, it also provides an alternative for women who still wish to have children”, adds Dr. Pieter Venema, urologist and experienced Urogyn trainer from the Netherlands.

Urolastic™ is an extremely biocompatible rubbery compound that forms in place after injection. The mixture forms as small flexible beads, which are over time encapsulated in scar tissue. Urolastic™ is injectable and does not shrink or degrade, thus remains effective in the longer term. The material also shows on X-rays and ultrasound and can be removed if required.
Following the earlier communications on Urolastic™ this is a promising step towards offering a minimally-invasive, outpatient, long-lasting treatment of women suffering from SUI.

About Urogyn: Urogyn was founded in 2009 with the ambition of developing new products in the field of urology and gynaecology, based upon a two-component polymer technology. The first products are now used in the treatment of Stress Urinary Incontinence (SUI) for both men and women. More products are expected to be commercially launched in the near future for birth control and treating faecal incontinence (www.urogynbv.com).

About Leader Biomedical: Leader Biomedical is committed to improving global access to innovative biomaterials and implantable medical devices and extending the reach of patients and caregivers by developing new technologies, delivering world class contract manufacturing services, and providing healthcare solutions. Leader Biomedical offers a wide range of therapeutic solutions, focusing on orthopaedic, dental, wound care and sports medicine. Our orthopaedic products can be used in both surgical and non-surgical procedures related to treating conditions ranging from musculoskeletal trauma, infections, malignancies, congenital disorders, reconstructive dental surgery, and sports injuries (www.leaderbiomedical.com).

Herikerbergweg 300, Diana Building
1101 CT Amsterdam
The Netherlands

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release First patient in Malaysia successfully treated with Urolastic™ - collaboration between Leader Biomedical and Urogyn yields first results here

News-ID: 738521 • Views: 561

More Releases from Leader Biomedical

Leader Biomedical announces acquisition of International Orthopaedics Holding Gm …
Amsterdam | Geisingen | 27 February 2018 Leader Biomedical is pleased to announce the phased acquisition of International Orthopaedics Holding GmbH (International Orthopaedics), a manufacturer and distributor of orthopaedic implants based in Geisingen, Germany. The companies have entered into a notarial deed on the 20th of February, 2018. This phased acquisition is in line with Leader Biomedical’s vision to expand its therapeutic solutions offering in Germany and to enhance its infrastructure
ANVISA approval for EMCM facilitates the progress of Leader Biomedical operation …
6 April 2017- AMSTERDAM/SAO PAULO- Leader Biomedical is proud to announce that our manufacturing facility in Nijmegen, European Medical Contract Manufacturing B.V. (EMCM) has received approval by the Brazilian competent authority, Agência Nacional de Vigilância Sanitária (ANVISA). This approval follows the previously announced, ANVISA approval of our facilities in Brazil, Inovações Biológicas Comercial LTDA (Leader Biomedical Brazil), which validated the warehouse facilities and presence of technical staff, ensuring quality standards
Leader Biomedical and Urogyn collaborate to bring innovative new procedure Urola …
10 January 2017- Amsterdam, The Netherlands- Urogyn B.V. and Leader Biomedical are proud to announce that Urolastic™ - an innovative Urinary Stress incontinence product - has been introduced into the product registration process in India. This marks the first step towards bringing a novel therapeutic solution to patients and caregivers in India. Many women suffer from Stress Urinary Incontinence (SUI), radically affecting their quality of life due to restraining

All 4 Releases


More Releases for Urolastic™ SUI Urogyn

Global Perfume Market 2019 - Lancome, ANNA SUI, Estee Lauder, Clinique
This new report by Eon Market Research, titled “Global Perfume Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Perfume industry at a global as well as regional and country level. Key facts analyzed in this report include the Perfume market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Leader Biomedical and Urogyn collaborate to bring innovative new procedure Urola …
10 January 2017- Amsterdam, The Netherlands- Urogyn B.V. and Leader Biomedical are proud to announce that Urolastic™ - an innovative Urinary Stress incontinence product - has been introduced into the product registration process in India. This marks the first step towards bringing a novel therapeutic solution to patients and caregivers in India. Many women suffer from Stress Urinary Incontinence (SUI), radically affecting their quality of life due to restraining
snom: risultati degli europei gratis sui telefoni VoIP
Berlino, Germania, 5 giugno 2008 – snom technology, produttore di telefoni VoIP avanzati per aziende e privati basati sullo standard open SIP, offre a tutti gli utenti dei suoi telefoni un servizio di ticker sui risultati delle partite del campionato europeo di calcio, direttamente sul display del telefono snom. Inoltre, l’azienda organizza un concorso sui pronostici con 50 interessanti premi a tema. Servizio di ticker e concorso sono completamente gratuiti